Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B6NT
|
|||
| Drug Name |
Pyrazolo[1,5-a]pyrimidine derivative 11
|
|||
| Synonyms |
PMID26161824-Compound-141
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Company |
MITSUBISHI TANABE PHARMA CORPORATION TANIMOTO, Koichi OI, Mariko TSUBOI, Yasunori MORITANI, Yasunor
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H24Cl2N4O5S
|
|||
| Canonical SMILES |
CC1(CCS(=O)(=O)C1)NC(=O)C2=C3N=CC(=C(N3N=C2OCCO)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
|
|||
| InChI |
1S/C26H24Cl2N4O5S/c1-26(10-13-38(35,36)15-26)30-24(34)21-23-29-14-19(18-4-2-3-5-20(18)28)22(16-6-8-17(27)9-7-16)32(23)31-25(21)37-12-11-33/h2-9,14,33H,10-13,15H2,1H3,(H,30,34)
|
|||
| InChIKey |
UNFBOPQOKSVPNI-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.